60
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Future of Pharmaceutical Manufacturing Sciences

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The entire pharmaceutical sector is in an urgent need of both innovative technological solutions and fundamental scientific work, enabling the production of highly engineered drug products. Commercial‐scale manufacturing of complex drug delivery systems (DDSs) using the existing technologies is challenging. This review covers important elements of manufacturing sciences, beginning with risk management strategies and design of experiments (DoE) techniques. Experimental techniques should, where possible, be supported by computational approaches. With that regard, state‐of‐art mechanistic process modeling techniques are described in detail. Implementation of materials science tools paves the way to molecular‐based processing of future DDSs. A snapshot of some of the existing tools is presented. Additionally, general engineering principles are discussed covering process measurement and process control solutions. Last part of the review addresses future manufacturing solutions, covering continuous processing and, specifically, hot‐melt processing and printing‐based technologies. Finally, challenges related to implementing these technologies as a part of future health care systems are discussed. © 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3612–3638, 2015

          Related collections

          Most cited references106

          • Record: found
          • Abstract: found
          • Article: not found

          Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.

          The formulation and delivery of biopharmaceutical drugs, such as monoclonal antibodies and recombinant proteins, poses substantial challenges owing to their large size and susceptibility to degradation. In this Review we highlight recent advances in formulation and delivery strategies--such as the use of microsphere-based controlled-release technologies, protein modification methods that make use of polyethylene glycol and other polymers, and genetic manipulation of biopharmaceutical drugs--and discuss their advantages and limitations. We also highlight current and emerging delivery routes that provide an alternative to injection, including transdermal, oral and pulmonary delivery routes. In addition, the potential of targeted and intracellular protein delivery is discussed.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Point of care diagnostics: status and future.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Understanding pharmaceutical quality by design.

              This review further clarifies the concept of pharmaceutical quality by design (QbD) and describes its objectives. QbD elements include the following: (1) a quality target product profile (QTPP) that identifies the critical quality attributes (CQAs) of the drug product; (2) product design and understanding including identification of critical material attributes (CMAs); (3) process design and understanding including identification of critical process parameters (CPPs), linking CMAs and CPPs to CQAs; (4) a control strategy that includes specifications for the drug substance(s), excipient(s), and drug product as well as controls for each step of the manufacturing process; and (5) process capability and continual improvement. QbD tools and studies include prior knowledge, risk assessment, mechanistic models, design of experiments (DoE) and data analysis, and process analytical technology (PAT). As the pharmaceutical industry moves toward the implementation of pharmaceutical QbD, a common terminology, understanding of concepts and expectations are necessary. This understanding will facilitate better communication between those involved in risk-based drug development and drug application review.
                Bookmark

                Author and article information

                Journal
                J Pharm Sci
                J Pharm Sci
                10.1002/(ISSN)1520-6017
                JPS
                Journal of Pharmaceutical Sciences
                John Wiley and Sons Inc. (Hoboken )
                0022-3549
                1520-6017
                November 2015
                17 August 2015
                : 104
                : 11 ( doiID: 10.1002/jps.2015.104.issue-11 )
                : 3612-3638
                Affiliations
                [ 1 ] Department of Pharmacy Faculty of Health and Medical SciencesUniversity of Copenhagen Denmark
                [ 2 ] Institute of Process and Particle EngineeringGraz University of Technology GrazAustria
                [ 3 ]Research Center Pharmaceutical Engineering GrazAustria
                Author notes
                [*] [* ] Correspondence to: Jukka Rantanen (E‐mail: jukka.rantanen@ 123456sund.ku.dk , Tel.: +45 35 33 65 85; Johannes Khinast (E‐mail: khinast@tugraz.at, Tel.: +43 316 873 30400, Fax: +43 316 873 10 30400)
                Article
                JPS24594
                10.1002/jps.24594
                4973848
                26280993
                08819f95-ea7d-4451-92d6-175a09236369
                © 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 06 December 2014
                : 26 June 2015
                : 29 June 2015
                Page count
                Pages: 27
                Categories
                Review
                Review
                Custom metadata
                2.0
                jps24594
                November 2015
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:04.08.2016

                Pharmacology & Pharmaceutical medicine
                quality by design (qbd),process analytical technology (pat),mathematical model,materials science,in silico modeling

                Comments

                Comment on this article